vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and DOUGLAS DYNAMICS, INC (PLOW). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $184.5M, roughly 1.5× DOUGLAS DYNAMICS, INC). DOUGLAS DYNAMICS, INC runs the higher net margin — 7.0% vs -45.7%, a 52.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 28.6%). DOUGLAS DYNAMICS, INC produced more free cash flow last quarter ($92.8M vs $-54.2M). Over the past eight quarters, DOUGLAS DYNAMICS, INC's revenue compounded faster (38.9% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
General Dynamics Corporation (GD) is an American industrial and technology company based in Reston, Virginia. It is primarily a developer and producer of advanced military equipment of a wide variety, such as nuclear submarines, main battle tanks, and armoured fighting vehicles. It is also the manufacturer of the civilian aviation Gulfstream business jets and a provider of information technology services. The company is the 3rd largest of the top 100 contractors of the U.S. federal government...
GH vs PLOW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $184.5M |
| Net Profit | $-128.5M | $12.8M |
| Gross Margin | 64.6% | 26.1% |
| Operating Margin | -43.0% | 10.5% |
| Net Margin | -45.7% | 7.0% |
| Revenue YoY | 39.4% | 28.6% |
| Net Profit YoY | -15.8% | 62.3% |
| EPS (diluted) | $-1.01 | $0.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $184.5M | ||
| Q3 25 | $265.2M | $162.1M | ||
| Q2 25 | $232.1M | $194.3M | ||
| Q1 25 | $203.5M | $115.1M | ||
| Q4 24 | $201.8M | $143.5M | ||
| Q3 24 | $191.5M | $129.4M | ||
| Q2 24 | $177.2M | $199.9M | ||
| Q1 24 | $168.5M | $95.7M |
| Q4 25 | $-128.5M | $12.8M | ||
| Q3 25 | $-92.7M | $8.0M | ||
| Q2 25 | $-99.9M | $26.0M | ||
| Q1 25 | $-95.2M | $148.0K | ||
| Q4 24 | $-111.0M | $7.9M | ||
| Q3 24 | $-107.8M | $32.3M | ||
| Q2 24 | $-102.6M | $24.3M | ||
| Q1 24 | $-115.0M | $-8.4M |
| Q4 25 | 64.6% | 26.1% | ||
| Q3 25 | 64.7% | 23.5% | ||
| Q2 25 | 65.0% | 31.0% | ||
| Q1 25 | 63.3% | 24.5% | ||
| Q4 24 | 61.6% | 24.9% | ||
| Q3 24 | 61.1% | 23.9% | ||
| Q2 24 | 59.1% | 30.7% | ||
| Q1 24 | 61.2% | 19.8% |
| Q4 25 | -43.0% | 10.5% | ||
| Q3 25 | -37.3% | 8.7% | ||
| Q2 25 | -45.9% | 19.0% | ||
| Q1 25 | -54.6% | 2.8% | ||
| Q4 24 | -62.4% | 9.0% | ||
| Q3 24 | -61.3% | 35.4% | ||
| Q2 24 | -56.8% | 18.2% | ||
| Q1 24 | -59.2% | -6.7% |
| Q4 25 | -45.7% | 7.0% | ||
| Q3 25 | -35.0% | 4.9% | ||
| Q2 25 | -43.0% | 13.4% | ||
| Q1 25 | -46.8% | 0.1% | ||
| Q4 24 | -55.0% | 5.5% | ||
| Q3 24 | -56.3% | 24.9% | ||
| Q2 24 | -57.9% | 12.2% | ||
| Q1 24 | -68.2% | -8.7% |
| Q4 25 | $-1.01 | $0.54 | ||
| Q3 25 | $-0.74 | $0.33 | ||
| Q2 25 | $-0.80 | $1.09 | ||
| Q1 25 | $-0.77 | $0.00 | ||
| Q4 24 | $-0.90 | $0.35 | ||
| Q3 24 | $-0.88 | $1.36 | ||
| Q2 24 | $-0.84 | $1.02 | ||
| Q1 24 | $-0.94 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | $144.0M |
| Stockholders' EquityBook value | $-99.3M | $281.4M |
| Total Assets | $2.0B | $626.7M |
| Debt / EquityLower = less leverage | — | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | $144.0M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $147.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $281.4M | ||
| Q3 25 | $-354.5M | $275.3M | ||
| Q2 25 | $-305.5M | $273.3M | ||
| Q1 25 | $-250.8M | $258.9M | ||
| Q4 24 | $-139.6M | $264.2M | ||
| Q3 24 | $-60.1M | $260.8M | ||
| Q2 24 | $-1.6M | $236.7M | ||
| Q1 24 | $68.3M | $217.2M |
| Q4 25 | $2.0B | $626.7M | ||
| Q3 25 | $1.3B | $694.9M | ||
| Q2 25 | $1.3B | $671.5M | ||
| Q1 25 | $1.3B | $621.0M | ||
| Q4 24 | $1.5B | $590.0M | ||
| Q3 24 | $1.5B | $665.6M | ||
| Q2 24 | $1.6B | $617.0M | ||
| Q1 24 | $1.7B | $577.1M |
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.56× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $95.9M |
| Free Cash FlowOCF − Capex | $-54.2M | $92.8M |
| FCF MarginFCF / Revenue | -19.3% | 50.3% |
| Capex IntensityCapex / Revenue | 9.9% | 1.7% |
| Cash ConversionOCF / Net Profit | — | 7.47× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $63.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $95.9M | ||
| Q3 25 | $-35.4M | $-8.5M | ||
| Q2 25 | $-60.3M | $-11.4M | ||
| Q1 25 | $-62.7M | $-1.3M | ||
| Q4 24 | $-64.5M | $74.4M | ||
| Q3 24 | $-51.1M | $-14.2M | ||
| Q2 24 | $-94.0M | $2.5M | ||
| Q1 24 | $-30.3M | $-21.6M |
| Q4 25 | $-54.2M | $92.8M | ||
| Q3 25 | $-45.8M | $-11.4M | ||
| Q2 25 | $-65.9M | $-14.3M | ||
| Q1 25 | $-67.1M | $-3.5M | ||
| Q4 24 | $-83.4M | $70.2M | ||
| Q3 24 | $-55.3M | $-15.2M | ||
| Q2 24 | $-99.1M | $836.0K | ||
| Q1 24 | $-37.2M | $-22.4M |
| Q4 25 | -19.3% | 50.3% | ||
| Q3 25 | -17.3% | -7.1% | ||
| Q2 25 | -28.4% | -7.4% | ||
| Q1 25 | -33.0% | -3.0% | ||
| Q4 24 | -41.3% | 48.9% | ||
| Q3 24 | -28.9% | -11.8% | ||
| Q2 24 | -55.9% | 0.4% | ||
| Q1 24 | -22.1% | -23.4% |
| Q4 25 | 9.9% | 1.7% | ||
| Q3 25 | 3.9% | 1.8% | ||
| Q2 25 | 2.4% | 1.5% | ||
| Q1 25 | 2.2% | 1.9% | ||
| Q4 24 | 9.4% | 2.9% | ||
| Q3 24 | 2.2% | 0.8% | ||
| Q2 24 | 2.9% | 0.8% | ||
| Q1 24 | 4.1% | 0.8% |
| Q4 25 | — | 7.47× | ||
| Q3 25 | — | -1.07× | ||
| Q2 25 | — | -0.44× | ||
| Q1 25 | — | -9.03× | ||
| Q4 24 | — | 9.41× | ||
| Q3 24 | — | -0.44× | ||
| Q2 24 | — | 0.10× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PLOW
| Work Truck Solutions | $101.5M | 55% |
| Transferred At Point In Time | $83.1M | 45% |
